左乙拉西坦治疗成人癫痫的疗效及安全性分析

摘要

Objective To investigate the efficacy ,survivability and safety of levetiracetam (LEV) in treatment of adult ep‐ileptics.Methods 98 epileptics collected from February 2013 to June 2014 in our hospital were divided into the experimental group and control group ,49 cases in each group. The experimental group was treated with LEV ,while the control group was given routine drugs ;each group was treated for 40 days. The clinical effect and adverse reaction in both groups were observed. Results The effective rates in the experimental group and the control group were 81.6% and 61.2% respectively ,with a sig‐nificant difference (P<0.05). No significant differences were detected in adverse reactions ,including abnormal indexes ,ano‐rexia and somnolence etc (P>0.05). Skin rash or leukopenia occoured in individual patients was proved not to be caused by LEV. Conclusion As a new type drug ,LEV is proved to be with a high safety ,good survivability in epileptics during the ini‐tial and interim stages ,and has significant clinical effect for exclusive use.%目的：分析左乙拉西坦在成人癫痫患者中的疗效、耐受性及安全性。方法选取我院2013‐02—2014‐06收治的98例癫痫患者为研究对象，随机分为试验组（LEV治疗）和对照组（常规用药）各49例，疗程40d，观察疗效及不良反应。结果观察组有效率81. 6％，对照组为61. 2％，2组疗效比较差异有统计学意义（P＜0. 05）。2组指标异常、厌食、嗜睡等不良反应差异无统计学意义（P＞0. 05）。个别患者出现皮疹、白细胞下降症状并不是应用左乙拉西坦造成的。结论左乙拉西坦（LEV）作为一种新型药物，安全性较高，在癫痫治疗的初、中期患者耐受性好，单独使用其治疗效果也十分显著。